- Monotherapy with pembrolizumab in the first-line treatment of non-small cell lung cancer with a high expression of PD-L1 >= 50 %2020 | Faculty of Medicine in Pilsen
- Case report of a patient with generalized NSCLC with high PD-L1 expression treated with pembrolizumab2020 | Publication without faculty affiliation
- Monitoring EBV infection, MSI, PDL-1 expression, Her-2/neu amplification as a biomarker for PD-1 inhibition in gastric cancer2022 | First Faculty of Medicine, Third Faculty of Medicine